Diagnostic Accuracy of Arterial Spin-Labeling, Dynamic Contrast-Enhanced, and DSC Perfusion Imaging in the Diagnosis of Recurrent High-Grade Gliomas: A Prospective Study.
Journal
AJNR. American journal of neuroradiology
ISSN: 1936-959X
Titre abrégé: AJNR Am J Neuroradiol
Pays: United States
ID NLM: 8003708
Informations de publication
Date de publication:
02 2023
02 2023
Historique:
received:
28
07
2022
accepted:
30
12
2022
pmc-release:
01
02
2024
pubmed:
27
1
2023
medline:
4
2
2023
entrez:
26
1
2023
Statut:
ppublish
Résumé
For patients with high-grade gliomas, the appearance of a new, enhancing lesion after surgery and chemoradiation represents a diagnostic dilemma. We hypothesized that MR perfusion without and with contrast can differentiate tumor recurrence from radiation necrosis. In this prospective study, we performed 3 MR perfusion methods: arterial spin-labeling, DSC, and dynamic contrast enhancement. For each lesion, we measured CBF from arterial spin-labeling, uncorrected relative CBV, and leakage-corrected relative CBV from DSC imaging. The volume transfer constant and plasma volume were obtained from dynamic contrast-enhanced imaging without and with T1 mapping using modified Look-Locker inversion recovery (MOLLI). The diagnosis of tumor recurrence or radiation necrosis was determined by either histopathology for patients who underwent re-resection or radiologic follow-up for patients who did not have re-resection. There were 26 patients with 32 lesions, 19 lesions with tumor recurrence and 13 lesions with radiation necrosis. Compared with radiation necrosis, lesions with tumor recurrence had higher CBF ( In the differentiation of tumor recurrence from radiation necrosis in a newly enhancing lesion, the diagnostic value of arterial spin-labeling-derived CBF is similar to that of DSC and dynamic contrast-enhancement-derived blood volume.
Sections du résumé
BACKGROUND AND PURPOSE
For patients with high-grade gliomas, the appearance of a new, enhancing lesion after surgery and chemoradiation represents a diagnostic dilemma. We hypothesized that MR perfusion without and with contrast can differentiate tumor recurrence from radiation necrosis.
MATERIALS AND METHODS
In this prospective study, we performed 3 MR perfusion methods: arterial spin-labeling, DSC, and dynamic contrast enhancement. For each lesion, we measured CBF from arterial spin-labeling, uncorrected relative CBV, and leakage-corrected relative CBV from DSC imaging. The volume transfer constant and plasma volume were obtained from dynamic contrast-enhanced imaging without and with T1 mapping using modified Look-Locker inversion recovery (MOLLI). The diagnosis of tumor recurrence or radiation necrosis was determined by either histopathology for patients who underwent re-resection or radiologic follow-up for patients who did not have re-resection.
RESULTS
There were 26 patients with 32 lesions, 19 lesions with tumor recurrence and 13 lesions with radiation necrosis. Compared with radiation necrosis, lesions with tumor recurrence had higher CBF (
CONCLUSIONS
In the differentiation of tumor recurrence from radiation necrosis in a newly enhancing lesion, the diagnostic value of arterial spin-labeling-derived CBF is similar to that of DSC and dynamic contrast-enhancement-derived blood volume.
Identifiants
pubmed: 36702501
pii: ajnr.A7771
doi: 10.3174/ajnr.A7771
pmc: PMC9891339
doi:
Substances chimiques
Spin Labels
0
Contrast Media
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
134-142Informations de copyright
© 2023 by American Journal of Neuroradiology.
Références
Magn Reson Med. 2010 Mar;63(3):772-81
pubmed: 20187184
Mol Imaging Biol. 2017 Dec;19(6):857-866
pubmed: 28303489
J Cereb Blood Flow Metab. 2017 Sep;37(9):3184-3192
pubmed: 28058975
Eur Radiol. 2017 Oct;27(10):4129-4144
pubmed: 28332014
Radiother Oncol. 2018 Oct;129(1):68-74
pubmed: 29398151
Acad Radiol. 2013 Dec;20(12):1557-65
pubmed: 24200483
AJNR Am J Neuroradiol. 2005 Sep;26(8):1967-72
pubmed: 16155144
AJNR Am J Neuroradiol. 2015 Apr;36(4):686-93
pubmed: 25500312
Biometrics. 1988 Sep;44(3):837-45
pubmed: 3203132
AJNR Am J Neuroradiol. 2018 Feb;39(2):260-264
pubmed: 29217742
J BUON. 2017 Jul-Aug;22(4):1061-1067
pubmed: 28952228
Acad Radiol. 2010 Mar;17(3):282-90
pubmed: 20060750
J Neurooncol. 2020 May;147(3):681-690
pubmed: 32239431
Medicine (Baltimore). 2020 Dec 24;99(52):e23766
pubmed: 33350761
J Magn Reson Imaging. 2019 Aug;50(2):573-582
pubmed: 30614146
Magn Reson Med. 2015 Jan;73(1):102-16
pubmed: 24715426
Acta Radiol. 2013 May;54(4):448-54
pubmed: 23592805
Cancer Med. 2019 Sep;8(12):5564-5573
pubmed: 31389669
Magn Reson Med. 2018 May;79(5):2564-2575
pubmed: 28913930